5 hours Ago By ABMN Staff
Diversify Wealth Management LLC increased its position in shares of Eli Lilly and Company ( NYSE:LLY – Free Report ) by 25.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,876 shares of the company’s stock after acquiring an additional 1,193 shares during the period.
Diversify Wealth Management LLC’s holdings in Eli Lilly and Company were worth $4,700,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also bought and sold shares of the company. Ellsworth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 456.
1% in the 4th quarter. Ellsworth Advisors LLC now owns 2,202 shares of the company’s stock valued at $1,700,000 after purchasing an additional 1,806 shares during the last quarter. RoundAngle Advisors LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at $1,524,000.
Successful Portfolios LLC grew its holdings in Eli Lilly and Company by 1.4% during the 4th quarter. Successful Portfolios LLC now owns 1,264 shares of the company’s stock worth $976,000 after acquiring an additional 17 shares during the period.
Mandatum Life Insurance Co Ltd raised its position in shares of Eli Lilly and Company by 13.2% in the 4th quarter. Mandatum Life Insurance Co Ltd now owns 326 shares of the company’s stock worth $252,000 after acquiring an additional 38 shares in the last quarter.
Finally, Client 1ST Advisory Group LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $1,217,000. Institutional investors and hedge funds own 82.53% of the company’s stock.
Wall Street Analyst Weigh In A number of brokerages have weighed in on LLY. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st.
Bank of America reiterated a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a report on Friday, November 15th.
They issued an “outperform” rating and a $1,000.00 price target for the company. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th.
Finally, Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.
00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,002.
22. Insider Activity In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th.
The shares were sold at an average price of $803.38, for a total transaction of $723,042.00.
Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.
11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink . Insiders own 0.
13% of the company’s stock. Eli Lilly and Company Trading Up 2.2 % Shares of LLY stock opened at $741.
98 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.
97 and a current ratio of 1.27. The company has a market capitalization of $704.
38 billion, a price-to-earnings ratio of 80.21, a PEG ratio of 1.52 and a beta of 0.
41. Eli Lilly and Company has a 52-week low of $614.82 and a 52-week high of $972.
53. The company has a 50-day simple moving average of $779.00 and a two-hundred day simple moving average of $852.
83. Eli Lilly and Company ( NYSE:LLY – Get Free Report ) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.
18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34).
Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%.
The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion.
During the same period in the previous year, the business posted $0.10 earnings per share. The business’s revenue was up 20.
4% compared to the same quarter last year. Research analysts anticipate that Eli Lilly and Company will post 12.98 EPS for the current fiscal year.
Eli Lilly and Company Increases Dividend The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a $1.50 dividend.
The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30.
This represents a $6.00 annualized dividend and a dividend yield of 0.81%.
Eli Lilly and Company’s payout ratio is presently 56.22%. Eli Lilly and Company declared that its board has approved a share buyback program on Monday, December 9th that authorizes the company to repurchase $15.
00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
Eli Lilly and Company Company Profile ( Free Report ) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. See Also Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.
com's FREE daily email newsletter ..
